Long-term antibiotic treatment for Crohn's disease: Systematic review and meta-analysis of placebo-controlled trials

Clinical Infectious Diseases

Volumn 50, Issue 4, 2010, Pages 473-480

  Feller, Martin ^a   Huwiler, Karin ^a   Schoepfer, Alain ^b,c   Shang, Aijing ^a   Furrer, Hansjakob ^a   Egger, Matthias ^a,d  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BUDESONIDE; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; DAPSONE; ETHAMBUTOL; ISONIAZID; METHYLPREDNISOLONE; METRONIDAZOLE; ORNIDAZOLE; PLACEBO; PREDNISOLONE; PYRIMETHAMINE; RIFABUTIN; RIFAMPICIN; RIFAXIMIN; SULFADOXINE;

ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CROHN DISEASE; DRUG DOSE REDUCTION; DRUG EFFICACY; HUMAN; LONG TERM CARE; MEDICAL LITERATURE; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SYSTEMATIC REVIEW; TREATMENT DURATION;

ANTI-BACTERIAL AGENTS; CLOFAZIMINE; CROHN DISEASE; HUMANS; NITROIMIDAZOLES; ODDS RATIO; PLACEBOS;

EID: 75749113277     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/649923     Document Type: Article

References (58)

1. Korzenik JR. Is Crohn's disease due to defective immunity? Gut 2007; 56:2-5.
2. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411: 603-606. (Pubitemid 32531409)
3. Lala S, Ogura Y, Osborne C, et al. Crohn's disease and the NOD2 gene: a role for paneth cells. Gastroenterology 2003; 125:47-57. (Pubitemid 36799106)
4. Hisamatsu T, Suzuki M, Reinecker HC, Nadeau WJ, McCormick BA, Podolsky DK. CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology 2003; 124:993-1000. (Pubitemid 36389802)
5. Marks DJ, Harbord MW, MacAllister R, et al. Defective acute inflammation in Crohn's disease: a clinical investigation. Lancet 2006; 367: 668-678. (Pubitemid 43289157)
6. Eckburg PB, Relman DA. The role of microbes in Crohn's disease. Clin Infect Dis 2007; 44:256-262.
7. Pineton de Chambrun G, Colombel JF, Poulain D, Darfeuille-Michaud A. Pathogenic agents in inflammatory bowel diseases. Curr Opin Gastroenterol 2008; 24:440-447.
8. Liu Y, van Kruiningen HJ, West AB, Cartun RW, Cortot A, Colombel JF Immunocytochemical evidence of Listeria, Escherichia coli, and Streptococcus antigens in Crohn's disease. Gastroenterology 1995; 108: 1396-1404.
9. Feller M, Huwiler K, Stephan R, et al. Mycobacterium avium subspecies paratuberculosis and Crohn's disease: a systematic review and metaanalysis. Lancet Infect Dis 2007; 7:607-613.
10. Hugot JP, Alberti C, Berrebi D, Bingen E, Cezard JP. Crohn's disease: the cold chain hypothesis. Lancet 2003; 362:2012-2015. (Pubitemid 37548429)
11. Darfeuille-Michaud A, Boudeau J, Bulois P, et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 2004; 127:412-421.
12. Ryan P, Kelly RG, Lee G, et al. Bacterial DNA within granulomas of patients with Crohn's disease: detection by laser capture microdissection and PCR. Am J Gastroenterol 2004; 99:1539-1543. (Pubitemid 39180104)
13. Clark M, Colombel JF, Feagan BC, et al. American gastroenterological association consensus development conference on the use of biologies in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology 2007; 133:312-339.
14. Travis SP, Stange EF, Lemann M, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006; 55(Suppl 1):i16-i35.
15. Cummings JR, Keshav S, Travis SP. Medical management of Crohn's disease. BMJ 2008; 336:1062-1066.
16. Borgaonkar MR, MacIntosh DG, Fardy JM. A meta-analysis of antimycobacterial therapy for Crohn's disease. Am J Gastroenterol 2000; 95:725-729. (Pubitemid 30123910)
17. Robinson KA, Dickersin K. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. International journal of epidemiology 2002; 31:150-153. (Pubitemid 34284917)
18. Stange EF, Travis SP, Vermeire S, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut 2006; 55(Suppl 1):i1-15.
19. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index: National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70:439-444.
20. Hasselblad V, Hedges LV. Meta-analysis of screening and diagnostic tests. Psychol Bull 1995; 117:167-178.
21. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327:557-560.
22. Altman DG. Confidence intervals for the number needed to treat. BMJ 1998; 317:1309-1312. (Pubitemid 28502420)
23. Afdhal NH, Long A, Lennon J, Crowe J, O'Donoghue DP. Controlled trial of antimycobacterial therapy in Crohn's disease: clofazimine versus placebo. Dig Dis Sci 1991; 36:449-453.
24. Arnold GL, Beaves MR, Pryjdun VO, Mook WJ. Preliminary study of ciprofloxacin in active Crohn's disease. Inflamm Bowel Dis 2002; 8: 10-15. (Pubitemid 34130123)
25. Basilisco G, Ranzi T, Campanini C, Piodi L, Bianci PA. Controlled trial of rifabutin in Crohn's disease. Curr Ther Res 1989; 46:245-250. (Pubitemid 19213681)
26. Elliott PR, Burnham WR, Berghouse LM, Lennard-Jones JE, Langman MJ. Sulphadoxine-pyrimethamine therapy in Crohn's disease. Digestion 1982; 23:132-134.
27. Goodgame RW, Kimball K, Akram S, et al. Randomized controlled trial of clarithromycin and ethambutol in the treatment of Crohn's disease. Aliment Pharmacol Ther 2001; 15:1861-1866. (Pubitemid 34014340)
28. Graham DY, Al-Assi MT, Robinson M. Prolonged remission in Crohn's disease following therapy for Mycobacterium paratuberculosis infection. Gastroenterology 1995; 108:A826.
29. Kelleher D, O'Brien S, Weir D. Preliminary trial of clofazimine in chronic inflammatory bowel disease. Br Soc Gastroent 1982:A449.
30. Leiper K, Martin K, Ellis A, Watson AJ, Morris AI, Rhodes JM. Clinical trial: randomized study of clarithromycin versus placebo in active Crohn's disease. Aliment Pharmacol Ther 2008; 27:1233-1239. (Pubitemid 351697272)
31. Prantera C, Kohn A, Mangiarotti R, Andreoli A, Luzi C. Antimycobacterial therapy in Crohn's disease: results of a controlled, double-blind trial with a multiple antibiotic regimen. Am J Gastroenterol 1994; 89: 513-518. (Pubitemid 24106215)
32. Prantera C, Lochs H, Campieri M, et al. Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment Pharmacol Ther 2006; 23:1117-1125. (Pubitemid 43779351)
33. Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995; 108:1617-1621.
34. Rutgeerts P, Van Assche G, Vermeire S, et al. Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, doubleblind, placebo-controlled trial. Gastroenterology 2005; 128:856-861. (Pubitemid 40523538)
35. Selby W, Pavli P, Crotty B, et al. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. Gastroenterology 2007; 132:2313-2319. (Pubitemid 46890859)
36. Shaffer JL, Hughes S, Linaker BD, Baker RD, Turnberg LA. Controlled trial of rifampicin and ethambutol in Crohn's disease. Gut 1984; 25: 203-205. (Pubitemid 14131416)
37. Sutherland L, Singleton J, Sessions J, et al. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 1991; 32:1071-1075.
38. Swift GL, Srivastava ED, Stone R, et al. Controlled trial of anti-tuberculous chemotherapy for two years in Crohn's disease. Gut 1994; 35:363-368. (Pubitemid 24092907)
39. Modigliani R, Colombel JF, Dupas JL, et al. Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology 1996; 110:688-693. (Pubitemid 26075447)
40. Juni P, Altman DG, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 2001; 323:42-46. (Pubitemid 32682008)
41. Sterne JA, Egger M, Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ 2001; 323:101-105. (Pubitemid 32681979)
42. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55:749-753. (Pubitemid 43764536)
43. Dalziel T. Chronic interstitial enteritis. BMJ 1913; 2(2756):1068-1070.
44. Behr MA, Kapur V The evidence for Mycobacterium paratuberculosis in Crohn's disease. Curr Opin Gastroenterol 2008; 24:17-21.
45. Gui GP, Thomas PR, Tizard ML, Lake J, Sanderson JD, Hermon-Taylor J. Two-year-outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibiotics. J Antimicrob Chemother 1997; 39:393-400. (Pubitemid 27153799)
46. Borody TJ, Leis S, Warren EF, Surace R. Treatment of severe Crohn's disease using antimycobacterial triple therapy: approaching a cure? Dig Liver Dis 2002; 34:29-38.
47. Shafran I, Kugler L, El-Zaatari FA, Naser SA, Sandoval J. Open clinical trial of rifabutin and clarithromycin therapy in Crohn's disease. Dig Liver Dis 2002; 34:22-28. (Pubitemid 34202051)
48. Peyrin-Biroulet L, Neut C, Colombel JF. Antimycobacterial therapy in Crohn's disease: game over? Gastroenterology 2007; 132:2594-2598.
49. Reddy VM, O'Sullivan JF, Gangadharam PR. Antimycobacterial activities of riminophenazines. J Antimicrob Chemother 1999; 43:615-623.
50. Behr MA, Hanley J. Antimycobacterial therapy for Crohn's disease: a reanalysis. Lancet Infect Dis 2008; 8:344.
51. Van Rensburg CE, Joone GK, O'Sullivan JF, Anderson R. Antimicrobial activities of clofazimine and B669 are mediated by lysophospholipids. Antimicrob Agents Chemother 1992; 36:2729-2735.
52. Oliva B, Comanducci A, Chopra I. Antibacterial spectra of drugs used for chemotherapy of mycobacterial infections. Tuber Lung Dis 1998; 79:107-109. (Pubitemid 29078279)
53. Freeman CD, Klutman NE, Lamp KC. Metronidazole: A therapeutic review and update. Drugs 1997; 54:679-708.
54. Gilbert D, Moellering R, Eliopoulos G, Sande M. The Sanford guide to antimicrobial therapy. 37th ed. Sperryville, VA: Antimicrobial Therapy, 2007.
55. Davies NM, Jamali F. Pharmacological protection of NSAID-induced intestinal permeability in the rat: effect of tempo and metronidazole as potential free radical scavengers. Hum Exp Toxicol 1997; 16:345-349. (Pubitemid 27371241)
56. Narayanan S, Hunerbein A, Getie M, Jackel A, Neubert RH. Scavenging properties of metronidazole on free oxygen radicals in a skin lipid model system. J Pharm Pharmacol 2007; 59:1125-1130. (Pubitemid 47265360)
57. Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2008(1) :CD006893.
58. Hafner R, Bethel J, Power M, et al. Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers. Antimicrob Agents Chemother 1998; 42:631-639. (Pubitemid 28114820)